[Iridium curietherapy in conservative treatment of infiltrating cancer of the bladder].
Sixty patients with infiltrating bladder cancer were treated by partial cystectomy and iridium radiotherapy between 1977 and 1982. Actuarial 5-year survival was 90% for pT1, 51% for pT2 and 34% for pT3, bladder treatment being unsuccessful in 6 cases (11%). Long-term functional results were satisfactory. Iridium provides better radioprotection than radium and stricter dosage can be established. This conservative treatment for infiltrating bladder cancer is particularly indicated for pT1 and pT2 tumors, as single lesions and with a largest diameter not exceeding 4 cm. Results are better in cases with tumors of the mobile portion of bladder, the 5-year survival in these selected cases being 85% with a minimum of sequelae. This treatment may be used, generally combined with external radiotherapy, for tumors infiltrating deeply into muscle and more distant tissues.
D000230:Adenocarcinoma / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D001918:Brachytherapy / Q000379:methods*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D002295:Carcinoma, Transitional Cell / Q000532:radiotherapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007495:Iridium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011300:Preoperative Care; D011868:Radioisotopes / Q000627:therapeutic use*; D001743:Urinary Bladder / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000532:radiotherapy*
D011868:Radioisotopes; D007495:Iridium
La curiethérapie à l'iridium dans le traitement conservateur des cancers infiltrants de vessie.